These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9597197)

  • 1. Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification.
    Girolami A; Simioni P; Scarano L; Girolami B; Marchiori A
    Blood Rev; 1998 Mar; 12(1):45-51. PubMed ID: 9597197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor V antigen levels in APC resistance, in factor V deficiency and in combined APC resistance and factor V deficiency (pseudohomozygosis for APC resistance).
    Girolami A; Simioni P; Venturelli U; Girolami B; Zanon E
    Blood Coagul Fibrinolysis; 1997 Jun; 8(4):245-8. PubMed ID: 9199822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.
    Amiral J; Vissac AM; Seghatchian J
    Transfus Apher Sci; 2017 Dec; 56(6):906-913. PubMed ID: 29162399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
    Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
    Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
    Kraus M; Zander N; Fickenscher K
    Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF; Lensen RP; Bertina RM
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
    Reuner KH; Litfin F; Patscheke H
    Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
    Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
    Simioni P; Scarano L; Gavasso S; Sardella C; Girolami B; Scudeller A; Girolami A
    Br J Haematol; 1996 Feb; 92(2):435-41. PubMed ID: 8603014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous factor V-deficient patients show resistance to activated protein C whereas heterozygotes do not.
    Simioni P; Girolami A
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):825-7. PubMed ID: 7865690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels.
    Kamphuisen PW; Rosendaal FR; Eikenboom JC; Bos R; Bertina RM
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1382-6. PubMed ID: 10807757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory diagnosis of hereditary thrombophilia.
    Michiels JJ; Hamulyák K
    Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency.
    Zehnder JL; Jain M
    Blood Coagul Fibrinolysis; 1996 Apr; 7(3):361-2. PubMed ID: 8735145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple procedure that increases the specificity of the activated protein C resistance test in samples containing antiphospholipid antibodies.
    Jacobsen EM; Wisløff F
    Thromb Res; 1997 Jun; 86(5):385-91. PubMed ID: 9211629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
    van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
    Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.